WHO-defined ‘Myelodysplastic Syndrome With Isolated Del(5q)’ in 88 Consecutive Patients: Survival Data, Leukemic Transformation Rates and Prevalence of JAK2, MPL and IDH Mutations

Leukemia - United Kingdom
doi 10.1038/leu.2010.105
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

JAK2 and MPL Mutations in Myeloproliferative Neoplasms: Discovery and Science

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2008English

Acute Leukemic Transformation of Myelodysplastic Syndrome: Is Cytochemistry Still Relevant?

American Journal of Hematology
Hematology
2017English

Cryptic 5q Deletion in a Patient With Myelodysplastic Syndrome

British Journal of Haematology
Hematology
2017English

JAK2, CALR, and MPL Mutation Spectrum in Japanese Patients With Myeloproliferative Neoplasms

Haematologica
Hematology
2014English

Blood Consult: Treating Del(5q) Myelodysplastic Syndromes

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

The 2016 Revised World Health Organization Definition of ‘Myelodysplastic Syndrome With Isolated Del(5q)’; Prognostic Implications of Single Versus Double Cytogenetic Abnormalities

British Journal of Haematology
Hematology
2017English

Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide

Haematologica
Hematology
2008English

Response to Erythropoiesis‐stimulating Agents in Patients With WHO‐defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis (MDS/MPN‐RS‐T)

British Journal of Haematology
Hematology
2020English

Lenalidomide in 5q Minus Myelodysplastic Syndrome: How Long Is Enough?

Annals of Hematology
MedicineHematology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy